Literature DB >> 962425

The plasma protein binding and distribution of etomidate in dog, rat and human blood.

W E Meuldermans, J J Heykants.   

Abstract

The interactions of etomidate and its major metabolite (R 28 141) with plasma proteins were studied by equilibrium dialysis with a multiple cell system. A 4% human serum albumin solution was able to bind 78.5% of the etomidate, and 60.5% of R 25 141, whereas a 1.5% human gamma globulin solution bound etomidate for not more than 3% and did not bind R 28 141 at all. The association constants and free binding energies for the binding of etomidate and R 28 141 to human serum albumin were determined. Plasma protein binding of etomidate was 75.4% in the dog and 76.5% in man; in rat plasma 79.5% of the radioactivity was bound to the plasma proteins, however the etomidate was partly hydrolyzed, even in the presence of sodium fluoride. In the rat 29.7% was distributed to the blood cells, 55.9% bound to plasma proteins and 14.4% was present in plasma water; in the dog the distribution percentages were 42.1%, 43.7% and 14.2% respectively, and in man 37.7%, 47.6% and 14.7% respectively. The major metabolite of etomidate was distributed for 26.3% to the human blood cells, 47.4% was bound to plasma proteins and 26.2% was present in the plasma water; its plasma protein binding amounted to 64.3%. Etomidate was bound at or in the blood cells, whereas R 28 141 was not.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 962425

Source DB:  PubMed          Journal:  Arch Int Pharmacodyn Ther        ISSN: 0003-9780


  9 in total

1.  Pharmacokinetics of intravenous anaesthetics: implications for clinical use.

Authors:  M M Ghoneim; K Korttila
Journal:  Clin Pharmacokinet       Date:  1977 Sep-Oct       Impact factor: 6.447

2.  Relationship between etomidate plasma concentration and EEG effect in the rat.

Authors:  P De Paepe; G Van Hoey; F M Belpaire; M T Rosseel; P A Boon; W A Buylaert
Journal:  Pharm Res       Date:  1999-06       Impact factor: 4.200

3.  On the pharmacokinetics of domperidone in animals and man. IV. The pharmacokinetics of intravenous domperidone and its bioavailability in man following intramuscular, oral and rectal administration.

Authors:  J Heykants; R Hendriks; W Meuldermans; M Michiels; H Scheygrond; H Reyntjens
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1981       Impact factor: 2.441

4.  Hemodynamic Changes following Anesthesia Induction and LMA Insertion with Propofol, Etomidate, and Propofol + Etomidate.

Authors:  Hamzeh Hosseinzadeh; Samad Ej Golzari; Effat Torabi; Marjan Dehdilani
Journal:  J Cardiovasc Thorac Res       Date:  2013-10-05

Review 5.  Medical suppression of hypercortisolemia in Cushing's syndrome with particular consideration of etomidate.

Authors:  Jens Heyn; Carolin Geiger; Christian L Hinske; Josef Briegel; Florian Weis
Journal:  Pituitary       Date:  2012-06       Impact factor: 4.107

Review 6.  Clinical pharmacokinetics of the newer intravenous anaesthetic agents.

Authors:  P J Davis; D R Cook
Journal:  Clin Pharmacokinet       Date:  1986 Jan-Feb       Impact factor: 6.447

7.  Optimization, and in vitro and in vivo evaluation of etomidate intravenous lipid emulsion.

Authors:  Dandan Geng; Yan Li; Chunyan Wang; Bo Ren; Heping Wang; Chensi Wu; Yirong Zhang; Linlin Zhao; Ligang Zhao
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.819

8.  A Comparative Study of the Effect of Anesthesia Induction with the Use of Four Drug Combinations Including "Propofol," "Etomidate-Propofol," "Thiopental," and "Midazolam-Thiopental" on Hemodynamic Changes during the Insertion of Laryngeal Mask in Eye Surgery.

Authors:  Hamidreza Shetabi; Kamran Montazeri; Yalda Ghoodjani
Journal:  Adv Biomed Res       Date:  2022-02-28

Review 9.  Etomidate and its Analogs: A Review of Pharmacokinetics and Pharmacodynamics.

Authors:  Beatrijs I Valk; Michel M R F Struys
Journal:  Clin Pharmacokinet       Date:  2021-06-01       Impact factor: 6.447

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.